For research use only. Not for therapeutic Use.
Vemircopan（Cat No.:I038000）is an investigational oral drug being developed for the treatment of complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). It is a selective inhibitor of the complement factor C5, a key component in the complement system that plays a role in immune response and inflammation. By inhibiting C5, vemircopan prevents the formation of the membrane attack complex, which can damage red blood cells and tissues. Early clinical trials suggest it may offer a safer and more targeted alternative to current treatments, with potential benefits in managing these rare, chronic conditions.
| CAS Number | 2086178-00-7 |
| Synonyms | vemircopan |
| Molecular Formula | C29H28BrN7O3 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | (1R,3S,5R)-2-[2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl]-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide |
| InChI | InChI=1S/C29H28BrN7O3/c1-15-5-8-24(30)33-27(15)34-28(40)22-10-29(4)11-23(29)37(22)25(39)14-36-21-7-6-18(19-12-31-17(3)32-13-19)9-20(21)26(35-36)16(2)38/h5-9,12-13,22-23H,10-11,14H2,1-4H3,(H,33,34,40)/t22-,23+,29-/m0/s1 |
| InChIKey | OCXAGXCMZACNEC-CTWZREHQSA-N |
| SMILES | CC1=C(N=C(C=C1)Br)NC(=O)[C@@H]2C[C@]3(C[C@H]3N2C(=O)CN4C5=C(C=C(C=C5)C6=CN=C(N=C6)C)C(=N4)C(=O)C)C |
